Phase III data EVOLVE-ing nicely for Omthera's Epanova
This article was originally published in Scrip
Top-line data from a Phase III trial of Omthera Pharmaceuticals' lead product, the prescription-grade omega-3 fatty acid candidate, Epanova, show that it met its primary endpoint at all three doses tested, paving the way for a US NDA filing later this year.
You may also be interested in...
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.